Part A: Upamostat 200 mg

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 DiseaseNCT04723537RedHill Biopharma LimitedPhase 2, Phase 3Terminated2021-12-28Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.